Pharmafile Logo

Sylvant

J&J launches digital skincare challenge

Seeks start-ups focused on tackling areas such as skin health adherence treatment

EU flag

Janssen’s Tremfya cleared for European use

EC approves the medicine to treat adults with plaque psoriasis

- PMLiVE

EC expands Janssen’s prostate cancer drug reach

Zytiga plus predinson/prednisolone will now treat mHSPC patients

- PMLiVE

GSK’s ViiV gets US okay for two-drug HIV regimen

Juluca is a combination of ViiV’s Tivicay and Janssen’s Edurant

Magic of Lucid targets rare and specialist diseases

Lucid Group, the award-winning global medical communications company with offices in London, Buckinghamshire, Macclesfield and New York, has announced the launch of a new agency specialising in rare and specialist...

Lucid Group Communications Limited

- PMLiVE

Positive trial results for Janssen’s Symtuza boosts its HIV credentials

The STR provided ‘effective’ and ‘durable’ viral suppression

Janssen’s quest to prevent diseases taking hold

Johan van Hoof, general manager of Janssen Vaccines & Prevention, on 'recalibrating' public understanding of illness

- PMLiVE

Janssen’s quest to prevent diseases taking hold

Johan van Hoof, general manager of Janssen Vaccines & Prevention, on 'recalibrating' public understanding of illness

- PMLiVE

Janssen develops digital tools to help automate clinical trials

iSTEP platform combines mobile tech and smart packaging

- PMLiVE

CHMP recommends Teva’s generic version of Astellas’ Advagraf

Committee backs the drug for transplant rejection prophylaxis

- PMLiVE

SMC backtracks on Janssen’s multiple myeloma treatment Darzalex

Will now recommend the first-in-class treatment after securing a discount

- PMLiVE

Janssen’s Imbruvica fails to win NICE backing in lymphoma

But the agency recommends it on the CDF for another type of cancer

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links